In this week’s View, Dr. Eagle discusses rivaroxaban monotherapy vs combination therapy with antiplatelets on total thrombotic and bleeding events in atrial fibrillation with stable coronary artery disease, then looks at pre-operative atrial fibrillation and cardiovascular outcomes after non-cardiac surgery. Finally, Dr. Eagle explores a cohort study of claims databases that analyzes the risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Cardiac Surgery, COVID-19 Hub, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Pericardial Disease, Prevention, Atherosclerotic Disease (CAD/PAD), Anticoagulation Management and ACS, Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Aortic Surgery, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Acute Heart Failure, Interventions and ACS, Interventions and Coronary Artery Disease, Interventions and Vascular Medicine, Pulmonary Hypertension and Venous Thromboembolism

Keywords: Atrial Fibrillation, Coronary Artery Disease, Ischemic Attack, Transient, Ischemic Stroke, Heart Failure, Hemorrhage, Myocardial Infarction, Diabetes Mellitus, Renal Insufficiency, Chronic, COVID-19 Vaccines, Myocarditis, COVID-19, Pericarditis, Vaccination, RNA, Messenger, Platelet Aggregation Inhibitors, Acute Coronary Syndrome, Anticoagulants, Percutaneous Coronary Intervention, Coronary Artery Bypass

< Back to Listings